Latest Period
Q1 2026
Security Snapshot
RAPT Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RAPT) Institutional Ownership
CUSIP: 75382E109
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$1.04
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- RAPT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 0
- Total 13F value
- $0
- Share change
- -2,962,707
- Value change
- -$100,346,899
- Number of holders
- 0
- Shares outstanding
- 27,725,634
- SEC-reported price per share
- $1.04
Latest holder snapshot
4 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- RAPT - RAPT Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 75382E109.
- 0 institutions reported positions in Q1 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 3 to 0 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $100,346,899 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 0 institutions filings for Q1 2026.
Security key
75382E109
Latest holder period
Q1 2026
13F holders
0
13D/G owners
11
CIK / CUSIP context first
Open Q1 2026 holders
RAPT full holder history
RAPT Therapeutics, Inc. SEC filings
RAPT Therapeutics, Inc. company facts
RAPT Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 75382E109:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
RAPT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Medicxi IV LP | 17% | $19,446,240 | 22,352,000 | Medicxi IV GP Limited | 27 Dec 2024 | |||
| Deep Track Capital, LP | 9.9% | $12,280,920 | 14,116,000 | Deep Track Capital, LP | 23 Dec 2024 | |||
| Redmile Group, LLC | 9.9% | $12,121,231 | 13,932,449 | Redmile Group, LLC | 31 Dec 2024 | |||
| TCG Crossover GP II, LLC | 10% | $11,478,006 | 13,193,110 | TCG Crossover GP II, LLC | 27 Dec 2024 | |||
| Foresite Capital Fund VI LP | 9.3% | $10,875,000 | 12,500,000 | Foresite Capital Fund VI, L.P. | 23 Dec 2024 | |||
| VANGUARD GROUP INC | 6.3% | +202% | $7,202,554 | +$4,651,367 | 8,278,798 | +182% | The Vanguard Group | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC | 4.5% | $5,115,600 | 5,880,000 | Perceptive Advisors LLC | 31 Dec 2024 | |||
| BlackRock, Inc. | 1.7% | $2,006,761 | 2,306,622 | BlackRock, Inc. | 31 Mar 2025 | |||
| COLUMN GROUP II, LP | 4.9% | $1,395,126 | 1,603,593 | Peter Svennilson | 23 Dec 2024 | |||
| GLAZER CAPITAL, LLC | 5.4% | $50,334,004 | 1,486,094 | Glazer Capital, LLC | 02 Feb 2026 | |||
| FMR LLC | 0.4% | $418,041 | 480,507 | FMR LLC | 31 Jan 2025 |
As of 31 Mar 2026, 0 institutional investors reported holding 0 shares of RAPT Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RAPT). This represents 0% of the company’s total 27,725,634 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
26
Latest
Q1 2026
Rows shown
1-25 of 26
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 0 | $0 | -$100,346,899 | $1.04 | 0 |
| 2025 Q4 | 2,962,707 | $100,346,899 | -$332,096 | $33.87 | 3 |
| 2025 Q3 | 2,972,512 | $76,661,084 | +$42,075,407 | $25.79 | 3 |
| 2025 Q2 | 1,341,050 | $10,728,400 | -$158,903,455 | $8.00 | 2 |
| 2025 Q1 | 131,135,934 | $159,984,594 | +$4,424,695 | $1.22 | 89 |
| 2024 Q4 | 126,888,838 | $199,480,129 | +$130,912,564 | $1.58 | 89 |
| 2024 Q3 | 29,799,656 | $59,894,847 | -$5,399,235 | $2.01 | 92 |
| 2024 Q2 | 31,808,667 | $97,015,342 | -$20,514,565 | $3.05 | 100 |
| 2024 Q1 | 31,957,297 | $286,976,309 | -$135,887,644 | $8.98 | 120 |
| 2023 Q4 | 34,982,104 | $869,312,485 | +$6,735,986 | $24.85 | 108 |
| 2023 Q3 | 34,763,427 | $577,769,050 | +$11,319,522 | $16.62 | 96 |
| 2023 Q2 | 34,050,266 | $636,743,238 | +$14,411,769 | $18.70 | 97 |
| 2023 Q1 | 33,297,098 | $610,504,496 | +$19,762,513 | $18.35 | 104 |
| 2022 Q4 | 32,051,948 | $634,583,743 | +$67,138,151 | $19.80 | 92 |
| 2022 Q3 | 29,977,976 | $705,685,698 | -$6,718,488 | $24.06 | 96 |
| 2022 Q2 | 29,739,176 | $542,744,027 | +$30,137,398 | $18.25 | 83 |
| 2022 Q1 | 28,022,792 | $616,047,645 | -$11,376,493 | $21.99 | 82 |
| 2021 Q4 | 26,299,986 | $965,984,248 | +$58,612,650 | $36.73 | 96 |
| 2021 Q3 | 24,839,747 | $731,027,543 | +$65,328,555 | $31.05 | 104 |
| 2021 Q2 | 26,596,757 | $845,609,249 | +$179,542,242 | $31.79 | 107 |
| 2021 Q1 | 20,992,943 | $466,036,000 | +$14,749,147 | $22.20 | 77 |
| 2020 Q4 | 20,445,788 | $403,803,000 | +$1,193,976 | $19.75 | 80 |
| 2020 Q3 | 16,829,467 | $541,869,734 | +$65,277,706 | $32.20 | 66 |
| 2020 Q2 | 14,821,430 | $430,109,022 | +$93,891,523 | $29.02 | 52 |
| 2020 Q1 | 11,682,494 | $247,909,000 | +$53,863,363 | $21.27 | 37 |